Publication | Closed Access

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Breast OncologyOncologyImmunologyBreast CancerCancer TreatmentRandomised MulticentreMedicineRadiation OncologyNeoadjuvant PertuzumabHer2-positive Breast Cancer